Adipotide
Prohibitin-Targeting Peptide 1 (FTPP)
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
An experimental compound studied in animal research for fat reduction by targeting the blood supply to fat tissue. A human safety trial was started but not completed, and kidney effects remain a significant concern that has limited further development. This compound is not available as a treatment.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
The primary and dose-limiting toxicity in primate studies was renal proximal tubule dysfunction consistent with Fanconi-like syndrome, characterized by elevated serum creatinine, proteinuria, glucosuria, and electrolyte abnormalities (PMID 22072637). Effects were dose-dependent and described as partially reversible upon cessation of treatment. A later study using the CKGGRAKDC sequence as a liposomal ligand found elevated kidney uptake with ATS-targeted nanoparticles, providing mechanistic support for kidney-specific accumulation of the targeting domain (PMID 31725756). Renal toxicity was consistent across all primate species tested (rhesus macaques, baboons, cynomolgus monkeys). In a related D(KLAKLAK)2-containing compound (BMTP-78), renal toxicity was similarly observed as a class effect, alongside unexpected fatal cardiac arrhythmias at higher doses that were unique to BMTP-78 and not seen with adipotide (PMID 29205207). No human adverse event data has been published from NCT01262664.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-14]